Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

3,105JPY
2:22am BST
Price Change (% chg)

¥50 (+1.64%)
Prev Close
¥3,055
Open
¥3,090
Day's High
¥3,120
Day's Low
¥3,085
Volume
332,400
Avg. Vol
2,128,138
52-wk High
¥4,015
52-wk Low
¥2,107

4519.T

Chart for 4519.T

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company operates in two business segments. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transporta... (more)

Overall

Beta: 0.65
Market Cap (Mil.): ¥1,763,011.00
Shares Outstanding (Mil.): 559.69
Dividend: 23.00
Yield (%): 1.43

Financials

  4519.T Industry Sector
P/E (TTM): 31.22 32.74 33.38
EPS (TTM): 100.90 -- --
ROI: 9.49 18.26 17.53
ROE: 9.73 18.93 18.34
Search Stocks

Roche rules out mega deals, open to smaller ones - paper

ZURICH - Roche has ruled out major "double-digit billion" purchases but is open to smaller deals, the Swiss drugmaker's chairman said in an interview with a German newspaper published on Thursday.

04 Sep 2014

Roche rules out mega deals, open to smaller ones - paper

ZURICH, Sept 4 - Roche has ruled out major "double-digit billion" purchases but is open to smaller deals, the Swiss drugmaker's chairman said in an interview with a German newspaper published on Thursday.

04 Sep 2014

RPT-Chugai down 9 pct after report Roche decided against buyout

TOKYO, Aug 25 - Shares of Chugai Pharmaceutical Co Ltd plunged 9 percent early on Monday after Bloomberg said Roche Holding AG had decided against bidding for the nearly 40 percent of the Japanese drugmaker that it does not already own.

25 Aug 2014

Chugai down 9 pct after report Roche decided against buyout

TOKYO, Aug 25 - Shares of Chugai Pharmaceutical Co Ltd plunged 9 percent early on Monday after Bloomberg said Roche Holding AG had decided against bidding for the nearly 40 percent of the Japanese drugmaker that it does not already own.

25 Aug 2014

Fitch: Roche Has Headroom for Chugai Deal; R&D Benefit Possible

(The following statement was released by the rating agency) LONDON, August 19 (Fitch) Roche would probably have enough headroom to acquire the outstanding minority stake in Chugai Pharmaceutical without affecting its 'AA'/Stable rating, depending on the final structure of any deal, Fitch Ratings says. We believe the main benefit of a deal, which has been reported as possible but not confirmed by either company, is that it would enable Roche to cut costs by removing management duplication an

19 Aug 2014

Deals of the day- Mergers and acquisitions

(Adds Chugai Pharmaceuticals, Dollar General, Sensata, Ingersoll-Rand and Mexichem)

18 Aug 2014

Shares in Japan's Chugai surge on report of Roche buyout offer

TOKYO - Shares in Japan's Chugai Pharmaceutical Co Ltd jumped 15 percent on Monday on a media report that its 60-percent shareholder, Roche Holding AG , was in talks to buy the rest of the company for about $10 billion (6 billion pounds).

18 Aug 2014

Shares in Japan's Chugai surge on report of Roche buyout offer

TOKYO - Shares in Japan's Chugai Pharmaceutical Co Ltd jumped 15 percent on Monday on a media report that its 60-percent shareholder, Roche Holding AG , was in talks to buy the rest of the company for about $10 billion.

18 Aug 2014

UPDATE 1-Shares in Japan's Chugai surge on report of Roche buyout offer

(Adds fund manager comment on market reaction, source comment casting doubt on buyout)

18 Aug 2014

CORRECTED-Nikkei choppy as market eyes Ukraine, Jackson Hole; Chugai jumps

(Corrects Topix in last paragraph to 1,270.35 from 15,332.46) * Chugai up 21 pct after remaining unopened for more than an hour * Investors focused on when Fed will hike interest rates - traders * Shippers outperform on rising freight charges By Ayai Tomisawa TOKYO, Aug 18 - Japan's Nikkei was choppy on Monday morning as geopolitical tensions checked risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a

18 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: GlobalData
£81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks